GL1X · GenesisL1 explorer

Ligand · UK4

UK4 · 2-[(4-{6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-{[(2S)-oxetan-2-yl]methyl}-1H-benzimidazole-6-carboxylic acid

UK4, 2-[(4-{6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-{[(2S)-oxetan-2-yl]methyl}-1H-benzimidazole-6-carboxylic acid (C31 H30 F N5 O4, 555.6 g/mol), in the MolNFT structures on GenesisL1: bound in 7 records (4…

Component
UK4
Formula
C31 H30 F N5 O4
Class
ligand
Structures
7
PDB entries
4

Binding sites

UK4 in 7 structures; the first of them:

  • 6X1A · Non peptide agonist PF-06882961, bound to Glucagon-Like peptide-1 (GLP-1) Receptor · UK4 R501 · binds SER31, LEU32, TRP33, VAL36, GLN37, LEU141, LYS197, LEU201 and 16 more
  • 7LCI · PF 06882961 bound to the glucagon-like peptide-1 receptor (GLP-1R):Gs complex · UK4 R501 · binds SER31, LEU32, TRP33, VAL36, GLN37, GLU138, LEU141, LYS197 and 13 more
  • 7LCJ · PF 06882961 bound to the glucagon-like peptide-1 receptor (GLP-1R):Gs complex · UK4 R501 · binds SER31, LEU32, TRP33, VAL36, GLN37, LEU141, LYS197, LEU201 and 15 more
  • 6X1A · Non peptide agonist pf-06882961, bound to glucagon-like peptide-1 (glp-1) receptor · UK4 R501 · binds SER31, LEU32, TRP33, VAL36, GLN37, LEU141, LYS197, LEU201 and 13 more
  • 7LCI · Pf 06882961 bound to the glucagon-like peptide-1 receptor (glp-1R):GS complex · UK4 R501 · binds SER31, LEU32, TRP33, VAL36, GLN37, GLU138, LEU141, LYS197 and 13 more
  • 7LCJ · Pf 06882961 bound to the glucagon-like peptide-1 receptor (glp-1R):GS complex · UK4 R501 · binds SER31, LEU32, TRP33, VAL36, GLN37, LEU141, LYS197, LEU201 and 11 more
  • 7LCK · Pf 06882961 bound to the glucagon-like peptide-1 receptor (glp-1R) · UK4 R501 · binds SER31, LEU32, TRP33, VAL36, GLN37, LEU141, LYS197, LEU201 and 10 more

Residues it binds most

LEU 7, PHE 7, GLN 7, THR 7, TRP 7, SER 7, CYS 6, ARG 7, LYS 7, VAL 7 (residue and the binding sites it lines).

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.